State governments are increasingly enacting new laws to regulate healthcare transactions, aiming to limit the influence of private equity firms. As of 2025, at least 15 states have implemented some form of healthcare transaction review law, with several expanding their scope. These laws frequently mandate pre-closing notifications, often with extended periods necessitating longer transaction timelines and earlier regulatory engagement. Certain states, require prior approval or a Certificate of Need for specific facilities, assessing the transaction’s impact on healthcare quality, accessibility, and cost. Failure to secure necessary approvals can result in enforcement actions or significant delays.
The Corporate Practice of Medicine (CPOM) doctrine continues to pose a substantial structural challenge for PE firms investing in healthcare providers, particularly in states where enforcement is robust. These states generally prohibit non-physicians, including business entities, from owning or controlling medical practices. Without a deep understanding of these nuanced state laws, private equity groups risk acquiring practices they are not legally permitted to own or control, leading to severe enforcement actions, divestiture orders, and significant financial losses. The General Counsel Law Firm proactively identifies these pitfalls, ensuring your investment structures are legally sound from inception.
Private equity firms commonly utilize Management Services Organization (MSO) models, where a non-clinical entity provides administrative services under contract with a physician-owned professional corporation (PC). However, regulators meticulously scrutinize these arrangements to ensure they do not constitute indirect control over clinical decision-making, staffing, compensation, or treatment protocols. Improperly structured MSO arrangements can trigger enforcement actions, regulatory penalties, or even invalidate the entire structure, thereby jeopardizing the investment.